Validating Biomarkers for the Prodrome and Transition to Psychosis in Shanghai

在上海验证前驱症状和向精神病转变的生物标志物

• 批准号: 8733754
• 负责人: Huijun Li
• 金额: $ 20万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-12 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8733754
• 关键词: Address; Adolescent and Young Adult; Affect; Age; Algorithms; American; Anisotropy; Asians; Attenuated; Australia; Biological; Biological Markers; Biomedical Research; Blood specimen; Boston; Brain; China; Chinese People; Chronic; Clinical; Clinical Research; Clinical assessments; Collaborations; Complement; Country; Deterioration; Development; Diabetes Mellitus; Diagnostics Research; Diffusion; Drug abuse; EP300 gene; Early Intervention; Early treatment; Edema; Europe; Event-Related Potentials; Florida; Functional Magnetic Resonance Imaging; Future; Genetic Risk; Goals; Heart Diseases; Image; Impairment; Income; Individual; Institutes; Intervention; Interview; Investigation; Israel; Japan; Joints; Lead; Longitudinal Studies; Magnetic Resonance Imaging; Massachusetts; Measures; Medial; Medical center; Memory; Mental Health; Metric; Morbidity - disease rate; Movement; Myelin; Neurocognition; Neurocognitive; North America; Paranoia; Pathology; Performance; Persons; Phase; Population; Population Study; Predictive Value; Prevention strategy; Preventive; Process; Psyche structure; Psychiatry; Psychotic Disorders; Radial; Radiology Specialty; Recording of previous events; Research; Research Personnel; Research Training; Resources; Rest; Risk; Role; Sampling; Schizophrenia; Singapore; Social Functioning; Staging; Structure; Symptoms; Syndrome; Taiwan; Technology; Time; Translating; United States National Institutes of Health; Universities; Water; Work; World Health Organization; abstracting; base; biopsychosocial; design; extracellular; follow-up; genetic analysis; gray matter; high risk; improved; instrument; medical schools; mental health center; neocortical; neuroinflammation; neuropsychological; novel strategies; programs; public health relevance; response; social; social stigma; water diffusion; white matter

DESCRIPTION (provided by applicant): "Validating Biomarkers for the Prodrome and Transition to Psychosis in Shanghai" 7. Project Summary/Abstract: The identification of people at risk of developing psychosis is central to the development of early intervention and prevention strategies for schizophrenia. There is a worldwide movement in the study of populations at the putatively prodromal, clinical high-risk (CHR) stage led mainly by researchers in Australia, Europe, and North America ("North American Prodrome Longitudinal Studies/NAPLS). Within the Asian Network for Early Psychosis, Taiwan and Singapore have started to address the putatively prodromal population. To our knowledge, we are the only group carrying out a CHR study, an R21 in collaboration with the Shanghai Mental Health Center (SMHC), MH093294 (Fogarty/NIH, "Broadening the Investigation of Psychosis Prodrome to Different Cultural Groups"). The preliminary study, which has already begun, contains four major components: a) clinical assessment of prodromal subjects using the Structured Interview for Prodromal Syndromes and Scale of Prodromal Symptoms (SIPS/SOPS) (translated into Chinese by the PI of the R21, Dr. Li); b) neurocognitive assessment with the MATRICS battery, c) stigma, and d) event related potentials. In addition, blood samples will be collected and stored for future genetic analyses. Our current proposal, in response to the RFA-AI-12-021: "U.S.-China Program for Biomedical Collaborative Research (R01)" will build upon and extend the R21 at the SMHC by expanding the sample substantially and bring in structural, DTI and resting state measures of magnetic resonance imaging (MRI). We will work collaboratively with researchers at the SMHC to design and initiate a sustainable CHR to psychosis longitudinal program of research in China. The SMHC, a World Health Organization designated research center for mental health, has excellent clinical and biomedical research technical resources that can carry out a first-rate study in collaboration with the US team. Our specific aims are to: 1. Identify clinical and biomarker abnormalities in CHR vs. Controls; 2. Replicate prediction of psychosis algorithms from the NAPLS study and; 3. Demonstrate increasing brain abnormalities with conversion to psychosis. Two hundred CHR and 100 controls, age 15-45, will be assessed at baseline and followed for one year, resulting in an estimated 40 converters to psychosis. With an estimated retention rate of 75%, 30 CHR who become psychotic, 120 who do not become psychotic and 75 controls will be assessed at conversion or 1 year follow-up with an extensive battery of clinical and biological measures.

描述（由申请人提供）：“验证上海前驱症状和向精神病转变的生物标志物”7。项目概要/摘要：识别有精神病风险的人是制定精神分裂症早期干预和预防策略的核心。在全球范围内，主要由澳大利亚、欧洲和北美的研究人员领导了一项对处于脓疱前驱期、临床高危期的人群的研究运动（“北美前驱期纵向研究/NAPLS”）。在亚洲早期精神病网络内，台湾和新加坡已开始处理脓疱前驱人群。据我们所知，我们是唯一一个与上海市精神卫生中心（SMHC）合作进行的R21研究（MH 093294）（Fogarty/NIH，“将精神病前驱症状的调查扩大到不同文化群体”）。已经开始的初步研究包括四个主要组成部分：a）使用前驱综合征结构化访谈和前驱症状量表（SIPS/SOPS）（由R21的PI Li博士翻译成中文）对前驱受试者进行临床评估; B）使用MATRICS成套测验进行神经认知评估; c）污名; d）事件相关电位。此外，还将采集和储存血液样本，用于未来的遗传分析。我们目前的提案，作为对RFA-AI-12-021的回应：“美国-中国生物医学合作研究计划（R 01）”将在SMHC的R21基础上进行扩展，大幅扩大样本，引入磁共振成像（MRI）的结构、DTI和静息状态测量。我们将与SMHC的研究人员合作，在中国设计并启动一个可持续的精神病纵向研究项目。SMHC是世界卫生组织指定的精神卫生研究中心，拥有优秀的临床和生物医学研究技术资源，可以与美国团队合作开展一流的研究。我们的具体目标是：1.确定与对照组相比，实验组的临床和生物标志物异常; 2.从NAPLS研究中复制精神病算法的预测; 3.表现出越来越多的大脑异常转化为精神病。200名年龄在15-45岁之间的患者和100名对照者将在基线时接受评估，并随访一年，估计有40名患者转化为精神病。估计留存率为75%，30例精神病患者、120例未精神病患者和75例对照患者将在转换或1年随访时进行广泛的临床和生物学测量。